Skeletal Muscle Relaxants Flashcards

1
Q

Identify appropriate therapy for reversing neuromuscular blockade induced by skeletal muscle relaxants (i.e., d-tubocurarine)

A

Acetylcholinesterase (AChE) inhibitor

[note that larger doses of nondepolarizing agents diminish the antagonizing effects of cholinesterase inhibitors due to blockade of channel pore, which occurs at higher doses]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

AChE inhibitors may be used for reversing neuromuscular blockade induced by skeletal muscle relaxants (i.e., d-tubocurarine). List anticipated adverse effects of this reversal

A
Bradycardia
Bronchoconstriction
Salivation
Nausea
Vomiting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

AChE inhibitors may be used for reversing neuromuscular blockade induced by skeletal muscle relaxants (i.e., d-tubocurarine). This reversal may produce adverse cholinergic effects such as bradycardia, bronchoconstriction, salivation, nausea, and vomiting. What drugs may be co-administered to minimize these adverse effects at muscarinic AChRs?

A

Anticholinergic agents (e.g., atropine, glycopyrrolate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA of nondepolarizing neuromuscular blocking agents such as d-tubocurarine

A

Competitive antagonism at the nAChR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Some nondepolarizing agents produce ______ release, which can cause wheals on the skin, bronchospasm, hypotension, and bronchial and salivary secretion. Premedication with an __________ can attenuate these effects

A

Histamine; anti-histamine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

At large doses, ______ can produce ACh receptor blockade at autonomic ganglia and at the adrenal medulla, which can result in a fall in BP and tachycardia

A

Tubocurarine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

________ is a nondepolarizing agent that causes significant histamine release, and has a very long duration of action, so its clinical use has declined in favor of more specific and shorter-acting neuromuscular blockers

A

d-tubocurarine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Anesthetics exhibit drug-drug interactions with nondepolarizing neuromuscular blocking agents — Specifically, inhaled anesthetics potentiate the neuromuscular blockade produced by nondepolarizing muscle relaxants in a dose-dependent manner. What inhaled anesthetic has the strongest potentiating effect?

A

Isoflurane

[followed by sevoflurane = desflurane = enflurane = halothane > nitrous oxide]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What effect do antibiotics have on nondepolarizing neuromuscular blocking agents?

A

Aminoglycosides (gentamicin, tobramycin, amikacin, streptomycin, neomycin, paramomycin, netilimicin, spectinomycin) have been shown to enhance neuromuscular blockade

Some abx reduce the release of ACh in the prejunctional neuron, likely due to blockade of specific P-type calcium channels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Other agents that block signaling at the NMJ (e.g., tetrodotoxin, local anesthetics, botulinum toxin), ________ the actions of nondepolarizing agents

A

Enhance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Effect of aging on neuromuscular response to nondepolarizing agents

A

Prolonged duration of action from nondepolarizing relaxants occurs in elderly pts with reduced hepatic and renal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Neuromuscular blockade by nondepolarizing muscle relaxants is _____ in pts with myasthenia gravis

A

Enhanced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pts with _____________ and those with ______________ disease are resistant to nondepolarizing muscle relaxants (likely due to the increased expression of _______, which requires an increase in dose)

A

Severe burns; upper motor neuron; nAChRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List 4 isoquinoline derived nondepolarizing muscle relaxants

A

Atracurium (intermediate acting)

Cisatracurium (intermediate acting)

Doxacurium (long acting)

Mivacurium (short acting)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List 4 steroid derived nondepolarizing muscle relaxants

A

Intermediate acting: vecuronium, rocuronium

Long-acting: pancuronium, pipecuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

______ and _____ are steroid muscle relaxants that tend to be more dependent on biliary excretion or hepatic metabolism for their elimination and are more likely to be used clinically than long-acting steroid relaxants

A

Vecuronium

Rocuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which type of neuromuscular blocking agents have the least tendency to cause histamine release — isoquinoline-derived or steroid-derived?

A

Steroid-derived

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which steroid-derived nondepolarizing muscle relaxant has the most rapid time of onset (60-120 seconds) and can be used as an alternative to succinylcholine?

A

Rocuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

_______ is the only depolarizing drug that is used clinically; it has an ultra-short duration of action due to rapid hydrolysis and inactivation in the liver and plasma. Prolonged neuromuscular blockade can occur in pts with a genetically abnormal variant of plasma _______. It is not effectively metabolized at the synapse by ________.

A

Succinylcholine

Cholinesterase

Acetylcholinesterase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Effects of succinylcholine are similar to ACh (i.e., succinylcholine is a ______ agonist), but with a _______ duration of action compared to ACh

A

nAChR; longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Phase I block vs. phase II block caused by succinylcholine

A

Phase I block caused by succinylcholine = depolarizing; augmented by cholinesterase inhibitors

Phase II block caused by succinylcholine = desensitizing; reversed by cholinesterase inhibitors (increase in ACh at NMJ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Describe initial response to a standard pharmacological dose of IV succinylcholine

A

Transient muscle fasciculations over the chest and abdomen within 30 seconds

Paralysis develops rapidly (<90 seconds) in arm, neck, and leg muscles initially, followed by respiratory muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

_______ is often used for rapid sequence induction (e.g., during emergency surgery when objective is to secure airway rapidly and prevent soiling of lungs with gastric contents) and for quick surgical procedures in which an ultrashort acting neuromuscular blocker is practical

A

Succinylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Administering succinylcholine during halothane anesthesia may lead to __________ as an adverse effect

A

Cardiac arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Stimulation of nAChRs and mAChRs by succinylcholine produces negative inotropic (cardiac muscle contraction strength) and chronotropic (heart rate) effects, which may be attenuated by administration of __________. Large doses can cause _______ inotropic and chronotropic effects

A

An anticholinergic (atropine); positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Pts with burns, nerve damage or neuromuscular disease, closed head injury, and other trauma can respond to succinylcholine by releasing ______ into the blood, which on rare occasions can cause ________

A

Potassium; cardiac arrest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Other AEs of succinylcholine include increased _______ pressure, increased _______pressure, and ______ pain

A

Intraocular; intragastric; muscle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Contraindications to succinylcholine

A

Personal or family hx of malignant hyperthermia

Myopathies associated with elevated serum CPK values

Acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Black box warning associated with succinylcholine

A

Rarely, acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death can occur after administration to apparently healthy children with an undiagnosed skeletal muscle myopathy (usually males <8 y/o but also reported in adolescents)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

The combination of succinylcholine and volatile anesthetics can result in malignant hyperthermia. Malignant hyperthermia is caused by abnormal release of calcium from stores in skeletal msucle and is treated with _________

Aside from volatile and local anesthetics, succinylcholine also has interactions with ________ and _______ drugs

A

Dantrolene

Antibiotics; antiarrhythmic

31
Q

Uses of neurmuscular blocking drugs

A

Surgical relaxation

Tracheal intubation

Control of ventilation — provides adequate gas exchange and prevents atelectasis in pts who have ventilatory failure; reduce chest wall resistance and improve thoracic compliance

Treatment of convulsions — attenuates peripheral motor manifestations associated with status epilepticus or local anesthetic toxicity; no effect on CNS because they do not cross BBB

32
Q

3 subgroups of AChE inhibitors

A

Alcohols — positively charged, reversible, short duration (ex: edrophonium)

Carbamic acid esters — can be positively charged or neutral, reversible, longer duration (ex: neostigmine, pyridostigmine, physostigmine)

Organophosphates — neutral, highly lipid soluble; irreversible (ex: echothiophate, parathion, malathion, sarin, soman)

33
Q

Solubility and CNS distribution of quaternary and charged AChE inhibitors (neostigmine, pyridostigmine, edrophonium, echothiophate)

A

Relatively insoluble (parenteral admin)

No CNS distribution

34
Q

Solubility and CNS distribution of tertiary and uncharged AChE inhibitors (physostigmine, donepezil, tacrine, rivastigmine, galantamine)

A

Well absorbed from all sites

CNS distribution

35
Q

Organophosphates are lipid-soluble and readily absorbed from the skin, lung, gut, and conjunctiva. CNS distribution occurs (except for ______, which is charged).

Since the interaction between organophosphates and AChE is covalent and irreversible, there is virtually little metabolism and excretion via common biotransformation pathways. Regeneration of AChE by rapid administration of ________ is required in order to reestablish the termination of ACh signaling at the NMJ

A

Echothiophate

Pralidoxime

36
Q

Organ system effects of AChE inhibitors

A

Depending on site of action, AChE inhibitors have the ability to stimulate mAChRs at autonomic effector organs AND stimulate (followed by depression or paralysis) all autonomic ganglia and skeletal muscle via nAChRs

37
Q

Effects of AChE inhibitors on CNS in low vs. high concentrations

A

Low: diffuse activation on EEG and a subjective altering response

High: generalized convulsions d/t neuronla hyperstimulation (may be followed by coma and respiratory arrest)

38
Q

Effects of AChE inhibitors on NMJ

A

Therapeutic concentrations prolong and intensify actions of ACh, which increases strength of contraction

High concentrations lead to fibrillation and fasciculations of muscle fibers

Continued inhibition of AChE results in progression of depolarizing neuromuscular blockade to nondepolarizing blockade (as seen with succinylcholine); some quaternary carbamate AChE inhibitors have additional direct nicotinic agonist effects at NMJ (e.g., neostigmine)

39
Q

Major therapeutic uses of AChE inhibitors

A

Eye: Glaucoma, accommodative esotropia

GI and urinary tracts: postoperative atony, neurogenic bladder

NMJ: myasthenia gravis, curare-induced neuromuscular paralysis

Heart: rarely for certain atrial arrhythmias

Alzheimer disease

40
Q

_______, ________, and _______ are the standard AChE inhibitors used in symptomatic treatment of myasthenia gravis (do not cross the BBB); due to relatively short duration of action of these agents, repeated dosing is required every 2-8 hours depending upon agent, dose, and clinical response

A

Pyridostigmine
Neostigmine
Ambenonium

41
Q

The short-acting agent _______ had been used as a diagnostic agent for MG; now replaced by ice pack test and immunologic and/or electrophysiologic testing

A

Edrophonium

42
Q

Define myasthenic crisis vs cholinergic crisis

A

Myasthenic crisis — life-threatening condition defined as weakness from acquired myasthenia gravis that is severe enought to necessitate intubation

Cholinergic crisis — potential major side effect of excessive AChE inhibitors; the main symptom is muscle weakness, similar to myasthenic crisis

43
Q

How is myasthenic crisis differentiated from cholinergic crisis clinically?

A

Give AChE inhibitor (edrophonium)

If pt is in myasthenic crisis, the symptoms will improve

If pt is in cholinergic crisis, symptoms will remain unchanged or worsen

44
Q

________ is commonly used to reverse neuromuscular blocking drug-induced paralysis

A

Neostigmine

[AChE inhibitors may also be used to tx paralytic ileus, atony of urinary bladder, and congenital megacolon]

45
Q

Identify and explain symptoms of muscarinic receptor antagonism

A
Cutaneous vasodilation
Anhidrosis
Anhydrotic hyperthermia
Nonreactive mydriasis
Delirium
Hallucinations
Reduced desire to urinate
46
Q

Appropriate pharmacologic therapy for symptoms such as cutaneous vasodilation, anhidrosis, anhydrotic hyperthermia, nonreactive mydriasis, delirium, hallucinations, and reduced desire to urinate due to reduced or blocked mAChR stimulation

A

Physostigmine is preferred because it crosses the BBB

47
Q

AChE intoxication/excess may manifest as miosis, salivation, sweating, bronchial constriction, vomiting, diarrhea, confusion, ataxia, generalized convulsions, coma, and/or respiratory paralysis. Identify appropriate drug therapy to minimize effects at both mAChRs and nAChRs

A

Atropine (effective at mAChRs)

Pralidoxime (cholinesterase regenerator at nAChRs)

Benzodiazepine (anticonvulsant)

48
Q

List 5 centrally acting spasmolytics (muscle relaxants)

A
Baclofen
Carisprodol
Cyclobenzaprine
Diazepam
Tizanidine
49
Q

2 non-centrally acting spasmolytics

A

Dantrolene

Botulinum toxin

50
Q

Centrally acting spasmolytic that is as effective as diazepam in reducing spasticity and causes less sedation; does not reduce overally muscle strength as much as dantrolene

A

Baclofen

51
Q

MOA of baclofen

A

Agonist at GABA(B) receptors

Results in hyperpolarization (due to increased K+ conductance) and inhibition of excitatory neurotransmitter release in the brain and spinal cord

52
Q

AEs of Baclofen

A

Drowsiness and increased seizure activity in epileptic pts (withdrawal must be done slowly); vertigo, dizziness, psychiatric disturbances, insomnia, slurred speech, ataxia, hypotonia, and muscle weakness

53
Q

Centrally acting spasmolytic with unclear MOA; acts as a CNS depressant and is a schedule IV controlled substance with adverse effects of dizziness and drowsiness. Metabolized by CYP2C19 so should be used with caution when coadministered with CYP inhibitors

A

Carisprodol

54
Q

Centrally acting spasmolytic that reduces tonic somatic motor activity by influencing both alpha and gamma motor neurons; structurally related to TCAs and produces antimuscarinic side effects + sedation, confusion, and transient visual hallucinations; metabolized by CYP450s so use with caution when coadministered with CYP inhibitors

A

Cyclobenzaprine

55
Q

MOA of diazepam

A

Promotes binding of GABA to GABA(A) receptor, enhancing GABA-induced ion currents

Leads to increased inhibitory transmission and a reduction in spasticity

[note: causes sedation, muscle relaxation, anxiolytic, and anticonvulsant effects; schedule IV controlled substance]

56
Q

Centrally acting spasmolytic that is an alpha2-adrenergic agonist similar to clonidine, decreases excitatory input to alpha motor neurons

A

Tizanidine

57
Q

AEs of tizanidine

A

Drowsiness
Hypotension
Dry mouth
Asthenia/muscle weakness

58
Q

MOA of dantrolene

A

Inhibition of ryanodine receptor (RyR); blocks release of calcium through SR and muscle contraction is impaired

Note that cardiac and smooth muscle are unaffected due to a different RyR channel subtype

[in contrast to centrally acting spasmolytics, dantrolene reduces skeletal muscle strength by interfering with excitation-contraction coupling in muscle fibers]

59
Q

AEs of dantrolene

A

Generalized muscle weakness

Sedation

Hepatitis

60
Q

Uses for dantrolene

A

Spasticity associated with upper motor neuron disorders (e.g., spinal cord injury, stroke, CP, or MS) and malignant hyperthermia

61
Q

MOA of botulinum toxin

A

Cleaves components of core SNARE complex involved in exocytosis, preventing release of ACh

62
Q

Clinical uses for botulinum toxin

A

Strabismus and blepharospasm associated with dystonia

Cervical dystonia

Temporary improvement in appearance of lines/wrinkles of the face

Severe primary axillary hyperhidrosis

Focal spasticity

Prophylaxis of chronic migraine

63
Q

AEs of botulinum toxin

A

Focal muscle weakness in area of injection, which may last several months

64
Q

AEs of carisoprodol

A

Dizziness
Drowsiness
Addictive potential

65
Q

AEs of cyclobenzaprine

A
Drowsiness/sedation
Dizziness
Xerostomia
Confusion
Transient visual hallucinations
66
Q

List immunologic drugs used for multiple sclerosis

A

Glucocorticoids
Glatiramer acetate
Interferons
Mitoxantrone

67
Q

Monthly bolus IV ________ are used for tx of primary or secondary progressive MS alone or in combo with other immunomodulatory or immunosuppressive meds

A

Glucocorticoids (typically 1000 mg of methylprednisolone)

68
Q

Mixture of random polymers of four amino acids (L-alanine, L-glutamic acid, L-lysine, and L-tyrosine) that is antigenically similar to myelin basic protein, which is an important component of the myelin sheath of nerves. Thought to induce and activate T cell suppressor cells specific for a myelin antigen; also proposed to interfere with APC function of certain immune cells opposing pathogenic T cell function

A

Glatiramer acetate

69
Q

Immunologic agents used to tx MS that act on BBB by interfering with T cell adhesion to the endothelium by binding VLA-4 on T cells or by inhibiting the T cell expression of MMP

A

Interferons (IFN-beta-1a, IFN-beta-1b)

70
Q

Antineoplastic agent used to tx MS, AML, and advanced, hormone-refractory prostate cancer by intercalating into DNA resulting in cross-links and strand breaks (related to anthracycline abx)

A

Mitoxantrone

71
Q

Tx option for MS that results in reduction of relapses by 1/3, a reduction of new MRI T2 lesions and the volume of enlarging T2 lesions, a reduction in number and volume of Gd-enhancing lesions, and a slowing of brain atrophy

A

Interferons

72
Q

List 10 AChE inhibitors

A
Ambenonium
Donepezil
Echothiophate
Edrophonium
Galantamine
Neostigmine
Physostigmine
Pyridostigmine
Rivastigmine
Tacrine
73
Q

2 antimuscarinic compounds

A

Atropine

Glycopyrrolate

74
Q

Cholinesterase reactivator

A

Pralidoxime